Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

StatusRecruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 45 → 53 locations
    • Eligibility criteria expanded, about 13 words
  2. Study sites: 44 to 45v5
  3. Study sites: 43 to 44v4
  4. Trial sites expanded: 40 → 43 locationsv3
  5. Recruitment opened
    • Trial sites expanded: 0 → 40 locations
    • Start date changed from estimate of May 25, 2026 to May 11, 2026
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Amgen
169 trials monitored
See 11 trials at risk
Obesity
3,888 trials monitored
See 157 trials at risk
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Trial Details
NCT Number NCT07575399
Lead Sponsor Amgen
Conditions
(from sponsor)		 Obesity or Overweight
Related terms Obesity, Overweight
Enrollment 300 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov